View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 06-Nov-2020 10:22:20

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • DHSC Supply Disruption - Medicines

Action category: Important information for immediate action

Title: Publication of a revised clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)

Broadcast content:
Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA), the use of remdesivir in the treatment of COVID-19 has been supported in the UK by an Early Access to Medicines Scheme (EAMS), implemented from 26th May 2020, and subsequently by an interim clinical commissioning policy, which has been in place since 3 July.

The clinical commissioning policy (available as an attachment below) has now been updated to reflect the more positive position on remdesivir supply into the UK (via the European Union Joint Procurement Agreement arrangements) and to reflect the latest available evidence, including the results of the World Health Organization’s (WHO’s) Solidarity trial.

Additional information: This alert does not need to be cascaded to Primary Care.

Alert reference: CEM/CMO/2020/035


Contact our helpdesk


Medicines and Healthcare products Regulatory Agency